Biostage(BSTG) Engineers New Financing At Desperate Terms

The good news for Biostage(BSTG) shareholders is that the company is not quite dead yet. With cash set to run out in the second quarter and several quarters away from early stage clinical trials for its esophageal implant , Biostage stock has been swiftly moving downward. From over $2 per share last May, to over $0.70 at Wednesday’s… Read More »